Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
DYN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.07 - $47.45
Previous CloseN/A
Volume117.44K
Average Volume (3M)2.49M
Market Cap
$1.40B
Enterprise Value$2.92B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Feb 27, 2025EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding101,765,960
10 Day Avg. Volume1,488,120
30 Day Avg. Volume2,489,948
Standard Deviation0.23
R-Squared0.05
Alpha0.00365
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.19K
Enterprise Value/Ebitda-9.34
Forecast
1Y Price Target
$51.57Price Target Upside273.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Dyne Therapeutics News
PremiumCompany Announcements
Dyne Therapeutics Advances Clinical Trials for DM1 and DMD
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyUpdated Ph1/2 ACHIEVE data for DYNE-101 confirms benefits across multiple measures (splicing, function, CNS) and a well-tolerated safety profile in DM1.
Regulatory PathwayFast track designation for DYNE-101 highlights unmet need and enables more frequent FDA interactions with potential for priority review and accelerated approval.
Bears Say
Investor ConcernsInvestor sentiments reflect uncertainty over the 6.8 mg/kg being chosen as the registrational dose.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $13.07 and its highest was $47.45 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $1.40B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.712 by -$0.248.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.94.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 101,765,960 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.712. Following the earnings report the stock price went up 4.266%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
---
Dyne Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.57 (273.15% Upside)
$51.57 (273.15% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $11.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.67%
12-Months-Change
Fundamentals
Return on Equity
-68.69%
Trailing 12-Months
Asset Growth
274.60%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
---
DYN Stock 12 Month Forecast
Average Price Target
$51.57
▲(273.15% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Best Analysts Covering DYN
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+49.00%
reiterated a buy rating 6 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +49.00% per trade.
---